Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians

Area of Science:

• Pharmacotherapy
• Evidence Synthesis
• Health Economics

Background:

• Randomized controlled trials (RCTs) are crucial but often lack comparative data for chronic obstructive pulmonary disease (COPD) treatments.
• Assessing relative efficacy and treatment algorithm fit for COPD pharmacotherapies presents challenges.
• Meta-analysis offers a comprehensive assessment of available evidence, but pairwise comparisons are limited by the absence of head-to-head trials.

Purpose of the Study:

• To provide an overview of network meta-analysis (NMA) as an evidence synthesis method for COPD pharmacotherapy.
• To discuss key considerations for conducting and interpreting NMAs in the context of COPD.
• To guide appropriate methodology selection and highlight implications of incorrect application.

Main Methods:

• Network meta-analysis (NMA) indirectly compares treatments using a common comparator across multiple studies.
• The GRADE reporting framework is essential for assessing the certainty of evidence.
• Illustrative example using simulated data to demonstrate NMA methodologies.

Main Results:

• NMA enables comparison of treatments lacking direct head-to-head trials, such as single-inhaler triple therapies for COPD.
• Correct application of NMA methods, regardless of specific approach, should yield similar outcomes.
• GRADE framework aids in critically appraising NMA findings.

Conclusions:

• Healthcare professionals must understand NMA methodology for critical appraisal and informed clinical decision-making in COPD pharmacotherapy.
• Appropriate NMA application is vital for accurate treatment comparisons and optimizing patient outcomes.
• This review offers guidance on NMA usage for evidence synthesis in COPD.